Q3 Revenue Drops 41% to $7.6M as Net Loss Widens
AQST sits 23% above its 52-week low of $2.93.
Summary
Q3 revenue fell 41% to $7.6M from $12.8M a year earlier, which the company attributes to the timing of Suboxone product orders — quarterly manufacturing revenue is lumpy, so the drop is partly calendar-driven rather than pure demand erosion. The net loss widened to $16.5M from $15.4M, and adjusted EBITDA loss grew to $12.2M from $8.6M, meaning cash burn is running hotter than a year ago. Cash stood at $90.3M on Sept. 30, 2026, against that burn rate. The real story remains Anaphylm: the FDA accepted the NDA resubmission as a Class 2 response with a PDUFA goal date of March 16, 2027, and 2026 guidance is unchanged. The stock's thesis now rests almost entirely on that March 2027 decision, not on this quarter's manufacturing revenue.
At the time of this announcement, AQST was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487M. The 52-week trading range was $2.93 to $6.85. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.